Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 1, 2009

Mitsubishi Tanabe Gains Asian Rights to EnVivo’s Cognition-Enhancing Drug

  • Mitsubishi Tanabe Pharma (MTPC) licensed EnVivo Pharmaceuticals’ cognition-enhancing therapy for development and commercialization in Japan and other Asian countries. The candidate, EVP-6124, is in Phase IIa trials in the U.S.

    MTPC will pay an initial license fee as well as clinical, regulatory, and commercial milestones. EnVivo will also receive royalties on sales of EVP-6124 in the MTPC territory, which includes Japan, Korea, Taiwan, Indonesia, and other countries in Asia.

    MTPC plans on initiating Phase I trials during 2010. EVP-6124 is an alpha-7 nicotinic acetylcholine receptor agonist currently being tested by EnVivo in Alzheimer's and schizophrenia patients.

    EnVivo obtained exclusive rights to the alpha-7 agonist program and a related patent estate from Bayer Healthcare in November 2004.

Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.